Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 10 21 versus ORTHO NOVUM 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 10 21 versus ORTHO NOVUM 10 11 28.
ORTHO-NOVUM 10-21 vs ORTHO-NOVUM 10/11-28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining, reducing sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Prevention of pregnancyTreatment of menorrhagiaTreatment of dysmenorrheaRegulation of menstrual cyclesEmergency contraception (off-label)
Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who have menarche and desire contraception)Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
1 tablet (1 mg norethindrone, 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of no tablets.
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
None Documented
None Documented
Norethindrone 5-14 hours (mean 8 hours), ethinyl estradiol 7-20 hours (mean 13 hours). Steady-state achieved in 5-10 days.
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Hepatic via cytochrome P450 3A4 (CYP3A4) for norethindrone and ethinyl estradiol; first-pass metabolism; enterohepatic recirculation; elimination as glucuronide and sulfate conjugates in urine and feces.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism with extensive conjugation (glucuronidation and sulfation). Norethindrone: metabolized via reduction, conjugation (glucuronidation), and hydroxylation; also involves CYP3A4 to a lesser extent.
Renal approximately 50-60% as metabolites, biliary/fecal approximately 30-40% as metabolites and unchanged drug.
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Norethindrone: 90-95% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 61% bound to albumin and 36% to SHBG; Ethinyl estradiol: 98% bound to albumin.
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution.
Norethindrone: 4 L/kg; Ethinyl estradiol: 4-5 L/kg. Indicates extensive tissue distribution.
Oral: norethindrone 50-80%, ethinyl estradiol 40-60% due to first-pass metabolism.
Oral: Norethindrone ~64%; Ethinyl estradiol ~45% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 mL/min) due to lack of safety data.
No specific dose adjustment guidelines for renal impairment. Use with caution in patients with renal impairment, as ethinyl estradiol and norethindrone may accumulate. Monitor for fluid retention and hypertension.
Contraindicated in Child-Pugh class B or C hepatic impairment. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment established.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) due to potential accumulation and hepatotoxicity. For mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose adjustment, but monitor liver function tests.
Not indicated for use in pediatric patients before menarche. Post-menarche: same adult dosing, 1 tablet orally once daily for 21 days, then 7 days off.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily for 28 days). Safety and efficacy in adolescents have not been specifically established; however, use is common off-label.
Not indicated for use in postmenopausal women. Not recommended for elderly patients due to lack of efficacy and increased thrombotic risk.
Not indicated for use after menopause. No specific geriatric dosing; however, elderly women should not use combination hormonal contraceptives due to increased risk of thromboembolic events and cardiovascular disease. Use alternative contraception if needed.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (myocardial infarction, thromboembolism, stroke) from combination hormonal contraceptive use. Risk increases with age and with smoking intensity (especially >15 cigarettes/day). Women >35 years who smoke should not use this medication.
Increased risk of thromboembolic disorders (e.g., DVT, pulmonary embolism), myocardial infarction, stroke; hepatic neoplasia (benign and malignant); gallbladder disease; hypertension; glucose intolerance; elevated triglyceride levels; exacerbation of depression; fluid retention; headache; irregular bleeding; potential for decreased efficacy with concomitant enzyme-inducing drugs; instruct to report visual disturbances or migraine; discontinue if jaundice occurs; monitor for signs of thrombosis.
["Thromboembolic disorders (DVT, PE, arterial thrombosis, stroke, MI) – increased risk especially in smokers >35 years, obese, or with hypertension","Cerebrovascular disease","Hepatic disease (including hepatic adenoma or impaired liver function)","Gallbladder disease","Hypertension","Glucose intolerance/diabetes mellitus","Headache (including migraine with or without aura)","Uterine bleeding irregularities","Depression","Possible increased risk of cervical cancer with long-term use"]
Thrombophlebitis or thromboembolic disorders; history of DVT or PE; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; liver tumors (benign or malignant) or active liver disease; hypersensitivity to any component; age >35 years and smoking cigarettes; uncontrolled hypertension; diabetes with vascular involvement; migraine with focal aura; major surgery with prolonged immobilization.
["Known or suspected pregnancy","Current or past thromboembolic disorders (DVT, PE, stroke, MI)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Estrogen-dependent neoplasia","Hepatic adenomas or carcinomas, or active liver disease (e.g., acute hepatitis)","Undiagnosed abnormal uterine bleeding","Heavy smoking (>15 cigarettes/day) in women ≥35 years"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may increase estrogen levels but clinical relevance is minimal. Avoid excessive alcohol consumption due to potential liver strain. Maintain consistent dietary habits to reduce gastrointestinal side effects.
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Maintain consistent diet. Antacids containing magnesium may reduce absorption if taken within 2 hours. Caution with St. John's Wort, as it may reduce contraceptive efficacy.
Pregnancy category X. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: associated with fetal adrenal suppression, virilization of female fetuses, and potential for long-term neurodevelopmental effects. Use contraindicated in pregnant women.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction, preterm birth, and transient metabolic disturbances. Contraindicated during pregnancy (FDA Category X).
Excreted into breast milk in small amounts (M/P ratio approximately 0.5). May reduce milk production and composition. Use during breastfeeding not recommended; alternative contraception advised.
Excreted in breast milk in small amounts; M/P ratio approximately 0.4. May reduce milk production and quality. Use alternative contraception during breastfeeding.
Contraindicated in pregnancy; no dosing adjustments are applicable. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment applicable. Discontinue if pregnancy occurs.
Category C
Category C
ORTHO-NOVUM 10-21 (norethindrone 10 mg with ethinyl estradiol 21 mcg) 21-day regimen: breakthrough bleeding/spotting is common during first 3 cycles; encourage continuation. If a dose is missed, take as soon as remembered and use backup contraception for 7 days. Higher estrogen content increases thromboembolic risk; avoid in smokers >35 years. Monitor blood pressure and liver function at baseline and periodically.
ORTHO-NOVUM 10/11-28 is a biphasic oral contraceptive containing ethinyl estradiol (35 mcg) and norethindrone (0.5 mg/1 mg). The biphasic dosing mimics natural hormonal fluctuations. It is indicated for contraception. Monitor for breakthrough bleeding, especially during the first few cycles. Counsel patients to take at the same time daily and use backup contraception if a dose is missed. Contraindicated in smokers over 35, history of thromboembolism, or migraine with aura.
Take one tablet daily at the same time for 21 days, then 7 pill-free days.Use backup contraception (e.g., condoms) for the first 7 days of the first pack.If you miss a pill, take it as soon as you remember; if more than 24 hours, take last missed and use backup for 7 days.Common side effects include nausea, breast tenderness, spotting, and mood changes; they often improve within 3 months.Seek medical attention for severe leg pain, chest pain, shortness of breath, or severe headache.Do not smoke while taking this medication, especially if over 35 years old.
Take one tablet daily at the same time, following the scheduled order in the pack.Missing pills increases risk of pregnancy; refer to package insert for missed dose instructions.Use backup non-hormonal contraception for 7 days if you miss a dose or start late.Common side effects: nausea, breast tenderness, breakthrough bleeding, and mood changes.Report severe headache, chest pain, leg swelling/pain, or visual disturbances immediately.Smoking while on this pill increases risk of serious cardiovascular events; avoid smoking.Do not take during pregnancy; stop if pregnancy is suspected.